Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison's disease in a high-risk population

被引:52
作者
Barker, JM [1 ]
Ide, A [1 ]
Hostetler, C [1 ]
Yu, LP [1 ]
Miao, DM [1 ]
Fain, PR [1 ]
Eisenbarth, GS [1 ]
Gottlieb, PA [1 ]
机构
[1] Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA
关键词
D O I
10.1210/jc.2004-0874
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Individuals with type 1 diabetes mellitus (T1D) at risk for Addison's disease (AD) can be identified with RIAs for autoantibodies to the adrenal antigen 21-hydroxylase (21-OHAA). Screening individuals with T1D for 21OH-AA shows a relatively high prevalence of positive autoantibodies (1.4%, 38 of 2696 subjects). After detection of 21-OHAA, individuals were evaluated with endocrine testing, including baseline cortisol, ACTH, and plasma renin activity and low (1 mug) and high (250 mug) dose cortrosyn stimulation. Typing for DR and DQ alleles and for the major histocompatibility complex class I-related chain A (MICA) gene polymorphisms was performed. Six individuals were diagnosed with AD; five were identified on initial endocrine evaluation. Follow-up over 2.9 yr yielded one additional diagnosis of AD. Endocrine testing showed a correlation between baseline ACTH and peak cortisol (r = -0.61; P < 0.0001), baseline and peak cortisol (r = 0.70; P < 0.0001), and stimulated cortisol after low- and high-dose testing (r = 0.92; P < 0.0001). DR3-DQ2/DR4-DQ8 with DRB1* 0404 was associated with expression of 21-OHAA. At 2 yr, individuals homozygous for MICA5.1 had AD-free survival of 60% compared with 100% AD-free survival in those who were not homozygous for MICA5.1. Homozygosity for MICA5.1 may increase progression to overt AD among 21-OHAA-positive individuals.
引用
收藏
页码:128 / 134
页数:7
相关论文
共 29 条
[1]  
ANDERSON JR, 1957, LANCET, V1, P1123
[2]   Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes [J].
Armstrong, L ;
Bell, PM .
BRITISH MEDICAL JOURNAL, 1996, 312 (7046) :1601-1602
[3]   AUTOIMMUNE ADDISONS-DISEASE AND 21-HYDROXYLASE [J].
BAUMANNANTCZAK, A ;
WEDLOCK, N ;
BEDNAREK, J ;
KISO, Y ;
KRISHNAN, H ;
FOWLER, S ;
SMITH, BR ;
FURMANIAK, J .
LANCET, 1992, 340 (8816) :429-430
[4]  
Betterle C, 1997, J CLIN ENDOCR METAB, V82, P939, DOI 10.1210/jc.82.3.939
[5]   Adrenal-cortex autoantibodies and steroid-producing cells autoantibodies in patients with Addison's disease: Comparison of immunofluorescence and immunoprecipitation assays [J].
Betterle, C ;
Volpato, M ;
Pedini, B ;
Chen, S ;
Smith, BR ;
Furmaniak, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :618-622
[6]   THE NATURAL-HISTORY OF ADRENAL-FUNCTION IN AUTOIMMUNE PATIENTS WITH ADRENAL AUTOANTIBODIES [J].
BETTERLE, C ;
SCALICI, C ;
PRESOTTO, F ;
PEDINI, B ;
MORO, L ;
RIGON, F ;
MANTERO, F .
JOURNAL OF ENDOCRINOLOGY, 1988, 117 (03) :467-475
[7]   HLA-DRB1 and MICA in autoimmunity -: Common associated alleles in autoimmune disorders [J].
Bilbao, JR ;
Martín-Pagola, A ;
De Nanclares, GP ;
Calvo, B ;
Vitoria, JC ;
Vázquez, F ;
Castaño, L .
IMMUNOLOGY OF DIABETES II: PATHOGENESIS FROM MOUSE TO MAN, 2003, 1005 :314-318
[8]   Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency [J].
Brewer, KW ;
Parziale, VS ;
Eisenbarth, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :202-202
[9]  
COLLS J, 1995, CLIN CHEM, V41, P375
[10]   REMISSION OF SUBCLINICAL ADRENOCORTICAL FAILURE IN SUBJECTS WITH ADRENAL AUTOANTIBODIES [J].
DEBELLIS, A ;
BIZZARRO, A ;
ROSSI, R ;
PAGLIONICO, VA ;
CRISCUOLO, T ;
LOMBARDI, G ;
BELLASTELLA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (04) :1002-1007